Second-Line Treatment After Ipilimumab/Nivolumab Progression
For metastatic renal cell carcinoma progressing on first-line ipilimumab/nivolumab, cabozantinib is the preferred second-line therapy, with other VEGFR-TKIs (axitinib, lenvatinib/everolimus, tivozanib) as acceptable alternatives based on prior exposure and performance status. 1, 2
Primary Recommendation: Antiangiogenic TKI Therapy
The 2025 European guidelines explicitly state that for ICI-refractory disease, evidence supports the use of antiangiogenic TKIs distinct from those administered in the frontline setting 1. Since you received dual ICI therapy (ipilimumab/nivolumab) without a TKI component, you are TKI-naive, which opens the full spectrum of VEGFR-targeted options.
Cabozantinib as First Choice
Cabozantinib is particularly effective as second-line treatment for metastatic RCC, especially after ICI therapy 1. The guidelines specifically recommend cabozantinib as the preferred option if it has not been used in frontline treatment 1, 2. Real-world data from the GUARDIANS group confirms that cabozantinib was most frequently administered (63.4%) as subsequent therapy after ipilimumab/nivolumab and showed superior OS and PFS compared to other second-line options 3.
Alternative TKI Options
Other acceptable TKI choices include:
- Axitinib - demonstrated improvements in PFS and ORR 1
- Lenvatinib/everolimus combination - showed improvements in PFS and ORR, with network meta-analysis ranking it first for OS (HR=0.44) and PFS (HR=0.13) compared to placebo, though with higher severe adverse events 1, 4
- Tivozanib - viable option with demonstrated PFS/ORR benefits 1
The choice among these should be sequenced based on:
- Patient performance status (ECOG)
- Prior treatment responses
- Toxicity tolerance profile
- Specific organ function considerations
What NOT to Do: ICI Rechallenge
Critical caveat: Do not rechallenge with anti-PD(L)-1 therapy in combination with other agents. The 2025 guidelines explicitly state that "evidence from two randomized controlled trials showed a lack of benefit and an increase in toxicity with anti-PD(L)-1 rechallenge in combination" 1. The CONTACT-03 trial specifically demonstrated that sequencing ICI therapy with atezolizumab and cabozantinib did not yield benefits in ORR, PFS, or OS over single-agent TKI 2.
Emerging Option: Belzutifan
For heavily pretreated patients or those who have progressed through both ICI and TKI agents, belzutifan (HIF-2α inhibitor) has activity and avoids the TKI side-effect profile 1, 2. This represents a mechanistically distinct approach that can be considered as subsequent therapy, particularly if TKI toxicity is a concern.
Clinical Trial Enrollment
The guidelines strongly emphasize that enrollment in clinical trials in the treatment-refractory setting is highly encouraged 1, as there remains a need for randomized evidence for selection of subsequent treatment lines.
Practical Algorithm
- First assess: Performance status, organ function, prior toxicity tolerance
- If good performance status (ECOG 0-1): Start cabozantinib monotherapy
- If concerns about TKI toxicity: Consider lenvatinib/everolimus (higher efficacy but more toxicity) vs. axitinib or tivozanib (better tolerated)
- If progression on TKI: Consider belzutifan or clinical trial
- Never: Rechallenge with ICI combinations
The evidence base here is robust from multiple 2025 European guidelines 1, 2 with consistent recommendations across guideline bodies, making this a high-confidence recommendation despite the lack of head-to-head randomized trials in this specific post-ICI/ICI setting.